Insulet's Trading Volume Drops 49.39% to $236 Million, Ranks 358th in Market

On June 23, 2025, Insulet's trading volume reached $236 million, marking a 49.39% decrease from the previous day. This placed the company at the 358th position in the day's stock market rankings.

Insulet's Omnipod 5 automated insulin delivery system has been a significant player in the diabetes technology market. Initially cleared by the FDA in January 2022 for individuals aged six and above with type 1 diabetes, it became the world's first tubeless, wearable, automated insulin delivery system. Since then, Insulet has expanded its technology to include more users, including children and individuals with type 2 diabetes who previously could not use automated insulin delivery systems.

Last year, Insulet presented data at the American Diabetes Association Scientific Sessions, highlighting the capabilities of the Omnipod 5 system for type 2 diabetes patients. This led to the system being cleared for both type 1 and type 2 diabetes in August 2024. The company has continued to innovate, partnering with Marvel to create a comic book hero with diabetes, further expanding its reach and appeal.

At this year's ADA Scientific Sessions in Chicago, Insulet's Senior Vice President and Chief Medical Officer, Dr. Trang Ly, discussed the company's latest developments. Ly expressed satisfaction with the product's adoption rate, attributing its success to its simplicity and ease of use, which allows it to reach a broader patient base compared to other products on the market.